Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

Abstract Background Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia. But such deep responses are also associated with severe...

Full description

Bibliographic Details
Main Authors: Martin Gauthier, Françoise Durrieu, Elodie Martin, Michael Peres, François Vergez, Thomas Filleron, Lucie Obéric, Fontanet Bijou, Anne Quillet Mary, Loic Ysebaert
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Cancer
Subjects:
Chronic lymphocytic Leukaemia
Minimal residual disease
CD4 T-cells
Immunosuppression
Chemo-immunotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-019-5971-z

Internet

http://link.springer.com/article/10.1186/s12885-019-5971-z

Similar Items